The highway towards a cure
TRICALS partners with pharmaceutical and biotech companies to find a cure for ALS
Let's work together
TRICALS' MAGNET
MAGNET (Multi-Adaptive Global Network of Efficient Trials) is a TRICALS initiative whose goal is to set a new standard for clinical trials within ALS. MAGNET offers to perform innovative, cost-efficient phase II and III clinical trials for the pharmaceutical industry.
About TRICALS
TRICALS (Treatment Research Initiative to Cure ALS) is the largest European research initiative to find a cure for ALS. TRICALS brings together pharmaceutical and biotech companies, ALS patients and top ALS centers across Europe. By working together, we accelerate clinical drug development for ALS.
Through our unique network and trial-ready ALS centres, we serve a well-defined patient population across the globe. Our centres are characterized by high patient enrolment and dedicated research staff. All sites have an established track record in industry- and investigator-initiated trials ranging from phase I to pivotal phase III trials.
TRICALS can provide a range of services for companies: from a full-package to only certified training. Are you interested in partnering with us? Contact us to see how TRICALS can support you in performing the best trial.
Corcept Therapeutics
TRICALS has partnered with Corcept Therapeutics for their DAZALS trial. “Our strong partnership with TRICALS has advanced research on cortisol modulation in people living with ALS.”
TRICALS services
Partnered with
Our clinical trials
Our TRICALS centres
Our TRICALS network consists of more than 60 centres in more than 19 European countries. They all work together on one common goal: finding a cure for ALS. All TRICALS centres are experienced in clinical trials and have dedicated staff.
Ferrer team
"TRICALS played a key role in achieving our recruitment timelines, ensuring operational excellence, and securing robust data in the ADORE and ADOREXT clinical trials sponsored by Ferrer. From study design through to data analysis and results communication, TRICALS' involvement was both constant and outstanding. Their unwavering commitment to the participating sites, study participants, and Ferrer as the sponsor significantly contributed to the operational success of both clinical trials."
